Clearbridge Health partners A*STAR’s GIS to offer Prosigna Breast Cancer Prognostic Gene Signature Assay in Singapore

SINGAPORE – 26th April 2018 – Clearbridge Health Limited, a healthcare company with a focus on the delivery of precision medicine in Asia, has partnered with A*STAR’s Genome Institute of Singapore (GIS) to offer the Prosigna Breast Cancer Prognostic Gene Signature Assay to patients in Singapore. This is a genomic analysis procedure to better help doctors diagnose the risk of cancer relapse.

Under the partnership, Clearbridge and Genome Institute of Singapore will jointly offer the FDA 510(k) cleared Prosigna assay, which has clinical utility in assessing the risk of Distant Recurrence, and the necessity of adjuvant chemotherapy among women with early-stage breast cancer after surgery.

The partnership is strongly aligned with Clearbridge’s focus on the delivery of precision medicine by empowering healthcare professionals to make more reliable and accurate diagnoses that will provide better insights into disease management.

From mid-April 2018, Clearbridge starts the College of American Pathologists (CAP)-accredited service provision under the Personalised OMIC Lattice for Advanced Research and Improving Stratification (POLARIS) programme (CAP certified). POLARIS is a strategic initiative for introducing and embedding OMIC information (e.g. genomics) into disease diagnosis and treatment in Southeast Asia. POLARIS provides a platform for clinicians to perform specific clinical grade assays for patient diagnosis/treatment stratification and for the industry to validate diagnostic assays and develop products stratified for Asian populations.

Said Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, “Clearbridge is pleased to join hands with A*STAR’s GIS to offer this FDA-approved breast cancer recurrence risk test that will enable clinicians to enhance treatment options for patients, given the increasing prevalence of breast cancer in Asia. It is our ongoing goal to address this clinical need by delivering molecular diagnostics to improve disease management and patient outcomes, as well as make precision medicine options more accessible to patients.”

Prof Ng Huck Hui, Executive Director of GIS added, “Therapeutic options are steadily moving away from the one-size-fits-all approach towards individualised solutions. This is because different people may react differently to various treatments – while a form of therapy may work for some patients, it may remain ineffective for other patients. The collaboration between GIS and Clearbridge will help to provide patients with more accurate diagnoses and treatments that are tailored to their needs.”
In November 2017, Clearbridge became the first and exclusive provider of the Prosigna Breast Cancer Prognostic Gene Signature Assay to patients in Singapore, Malaysia, Indonesia, and the Philippines, as well as on a non-exclusive basis throughout Asia, pending applicable local regulatory approvals.

-- END --

About the Prosigna® Breast Cancer Prognostic Gene Signature Assay

The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. Based on the PAM50 gene signature initially discovered by Charles Perou, PhD and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilises gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient’s risk of distant recurrence of the disease. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumour tissue previously diagnosed as invasive breast carcinoma.

In the United States, the Prosigna Assay is 510(k) cleared for use on the nCounter Dx Analysis System and is available for diagnostic use when ordered by a physician. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognise the CE Mark, as well as Canada, Israel, Australia, New Zealand and Hong Kong. In the U.S., the Prosigna Assay has indicated that in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with the standard of care, either as:

(1) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors or

(2) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1-3 nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with four or more positive nodes.

For more information, please visit [www.prosigna.com](http://www.prosigna.com).

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more
reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. Clearbridge (Stock symbol: 1H3) is listed on the Catalist board of the Singapore Exchange Securities Trading Limited. For more information, please visit www.clearbridgehealth.com

About A*STAR’s Genome Institute of Singapore (GIS)

The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact. The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research. The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact. For more information about GIS, please visit www.gis.a-star.edu.sg

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes, the wider research community and industry. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis. For more information on A*STAR, please visit www.a-star.edu.sg

Media Contacts

<table>
<thead>
<tr>
<th>Clearbridge Health Limited</th>
<th>Genome Institute of Singapore</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Joseph Hu</td>
<td>Lyn Lai</td>
</tr>
<tr>
<td>Regional Marketing Director</td>
<td>Officer, Office of Corporate Communications</td>
</tr>
<tr>
<td><a href="mailto:kenneth.hu@clearbridgehealth.com">kenneth.hu@clearbridgehealth.com</a></td>
<td><a href="mailto:lai_ylin@gis.a-star.edu.sg">lai_ylin@gis.a-star.edu.sg</a></td>
</tr>
<tr>
<td>+65 6251 0136</td>
<td>+65 6808 8258</td>
</tr>
</tbody>
</table>
This press release has been prepared by the Company, and its contents have been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”).

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, Telephone: +65 6533 9898.